Table 1.

Patient demographics and clinical summary

ID no. Age Sex Pretreatment statusTarget antigen No. of infusionsToxicity Response
Previous TxDisease sitesNo IL-2+IL-2TypeDuration
1017-145FIFNSkin, LNMART143F, MStable disease21.3
1017-246FChemoLu, LN, CWMART113F, M, RMinor2.0
1017-350FBio-chemo, IFNLu, liverMART113NoneProgressive disease
1017-455MIFNLugp10013F, MStable disease3.6
1017-556FChemoSkin, LNMART112F, MStable disease15.2
1017-653FBio-chemoLugp10013F, MMixed6.8
1017-750MBio-chemoLu, LNgp10013FStable disease14.7
1017-847FChemo, IFNLu, BrPIMART113F, MMinor15.3
1017-959MBio-chemoLu, livergp10015F, MStable disease7.0
1017-1038FBio-chemoLu, livergp10012FProgressive disease
49.9133010.9
  • The age, gender, pretreatment status, T cell regimen, toxicity, and clinical response following adoptive T cell therapy are summarized in Table 1. Overall, 43 infusions were administered to 10 patients with an average age of 50 (38–59). All patients presented with progressive disease following conventional therapy. T cell-related toxicity was limited to fever and myalgias and a skin rash in one patient. Eight of 10 patients experienced a minor, mixed, or stable response, with a median duration of 11 mo (2–21 mo).

  • * Chemo, chemotherapy; IFN, high-dose interferon.

  • Lu, lung; LN, lymph nodes; CW, chest wall; BrPI, brachial plexus.

  • F, fever; M, myalgia; R, rash.

  • § Duration in months.

  • Decreased LN disease.

  • Mixed response in lung nodules.

  • ** Regain of brachial function, decreased/absent PET activity in disease site.